RICHMOND, British Columbia, May 3, 2011 (GLOBE NEWSWIRE) -- BioCurex Inc. (OTCBB:BOCX) announced today that its wholly owned subsidiary, OncoPet Diagnostics, has entered into a distribution agreement for its companion animal OncoPet RECAF™ cancer detection test with Success Vision Biotek Inc. of Taipei, Taiwan. The agreement is exclusive for the distribution of companion animal RECAF tests throughout the country of Taiwan.
Success Vision is an international biotechnology company with expertise in diagnostics and medical device distribution.
During the Company's visit to Taipei, Mr. Michael Huang, CEO of Success Vision, stated that his company is very excited to work with OncoPet Diagnostics to introduce the RECAF test to the Taiwanese veterinary market. Huang believes that this product will greatly enhance veterinarians' ability to diagnose and treat cancer in companion animals at an affordable cost for pet owners and clinics. Success Vision sponsored four presentations in Taiwan by an OncoPet medical representative. Veterinarians and opinion makers in the field expressed their interest and eagerness to start using OncoPet's cancer test.
"We look forward to building upon this partnership to launch our RECAF test in Asia, which we believe will become increasingly important for the high population of companion animals in the region," said OncoPet Diagnostics President and BioCurex CEO Dr. Ricardo Moro-Vidal. "Success Vision has expressed their commitment to market our product aggressively, and we are very pleased with the response from the veterinarians they serve."
For more information on Success Vision, visit: oncopetdiagnostics.com/distributors/profile/Success_Vision_Profile.pdf
About BioCurex, Inc.
BioCurex, Inc. is a biotechnology company that is developing products based on patented and proprietary technology in the area of cancer diagnostics. The technology identifies a universal cancer marker known as RECAF.
RECAF is a molecule that is present on cancer cells but not detected in significant levels on healthy cells or benign tumor cells. It is the receptor for alpha-fetoprotein and is classified as an oncofetal antigen due to its presence on both fetal and malignant tissues. This characteristic makes RECAF a more accurate indicator of cancer than most current tumor markers.
BioCurex is commercializing its technology through licensing arrangements with companies that develop and market diagnostic tests for the large automated clinical laboratory setting, through development and marketing of non-automated clinical laboratory tests, through development of rapid, point-of-care test formats, and through marketing of its OncoPet RECAF test for cancer in companion animals.
BioCurex has signed licensing agreements for its cancer detection blood tests with Abbott Laboratories (NYSE:ABT) and with Alere (NYSE:ALR), formerly Inverness Medical Innovations (NYSE:IMA).
For further information on these agreements visit: http://sec.gov/Archives/edgar/data/1092562/000100487808000117/sb2amnd4s1april08.txt.
For more information about Biocurex, please visit www.BioCurex.com.
For more information about OncoPet Diagnostics Inc., please visit: www.OncoPetDiagnostics.com.
Forward-Looking Statements
The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements'' within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.